MOUNTAIN VIEW, Calif.-- Microcide Pharmaceuticals here has formed Iconix Pharmaceuti cals, a chemical genetics company aimed at extending the company's microbial genomics research into a broader technology platform. The new entity has acquired a $12.5 million venture investment from Abingworth Management, Institutional Venture Partners, and Kleiner Perkins Caufield & Byers.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.